Literature DB >> 22817750

Role of splice variants in the metastatic progression of prostate cancer.

Rachel M Hagen1, Michael R Ladomery.   

Abstract

AS (alternative splicing) and its role in disease, especially cancer, has come to forefront in research over the last few years. Alterations in the ratio of splice variants have been widely observed in cancer. Splice variants of cancer-associated genes have functions that can alter cellular phenotype, ultimately altering metastatic potential. As metastases are the cause of approximately 90% of all human cancer deaths, it is crucial to understand how AS is dysregulated in metastatic disease. We highlight some recent studies into the relationship between altered AS of key genes and the initiation of prostate cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22817750     DOI: 10.1042/BST20120026

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  16 in total

1.  Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells.

Authors:  Wenzhi Li; Zhanyu Wang; Longmei Wang; Xiangfei He; Guangjian Wang; Hongjun Liu; Fengfu Guo; Zhong Wang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 2.  Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.

Authors:  Debanwita Roy Burman; Shalini Das; Rahul Bhattacharya; Chandrima Das
Journal:  Mol Biol Rep       Date:  2021-01-05       Impact factor: 2.316

Review 3.  Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.

Authors:  Jacqueline Olender; Norman H Lee
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

4.  APEX1 regulates alternative splicing of key tumorigenesis genes in non-small-cell lung cancer.

Authors:  Li Peng; Yuwei Liu; Jing Chen; Mengxin Cheng; Ying Wu; Min Chen; Ya Zhong; Dan Shen; Ling Chen; Xujun Ye
Journal:  BMC Med Genomics       Date:  2022-07-02       Impact factor: 3.622

5.  Overexpression of ROD1 inhibits invasion of breast cancer cells by suppressing the translocation of β-catenin into the nucleus.

Authors:  Ya Zhou; Hanqing Zou; Enhao Wu; Lei Huang; Rui Yin; Yuxin Mei; Xun Zhu
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

6.  Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.

Authors:  Annelies Suetens; Marjan Moreels; Roel Quintens; Sabina Chiriotti; Kevin Tabury; Arlette Michaux; Vincent Grégoire; Sarah Baatout
Journal:  Int J Oncol       Date:  2014-02-03       Impact factor: 5.650

Review 7.  RNA splicing and splicing regulator changes in prostate cancer pathology.

Authors:  Jennifer Munkley; Karen Livermore; Prabhakar Rajan; David J Elliott
Journal:  Hum Genet       Date:  2017-04-05       Impact factor: 4.132

8.  A pan-cancer analysis of alternative splicing of splicing factors in 6904 patients.

Authors:  Rui Cheng; Lixing Xiao; Wenyang Zhou; Xiyun Jin; Zhaochun Xu; Chang Xu; Pingping Wang; Meng Luo; Mengyun Wang; Kexin Ma; Huimin Cao; Yan Huang; Xiaoyu Lin; Fenglan Pang; Yiqun Li; Qinghua Jiang
Journal:  Oncogene       Date:  2021-07-20       Impact factor: 9.867

Review 9.  Alternative splicing for diseases, cancers, drugs, and databases.

Authors:  Jen-Yang Tang; Jin-Ching Lee; Ming-Feng Hou; Chun-Lin Wang; Chien-Chi Chen; Hurng-Wern Huang; Hsueh-Wei Chang
Journal:  ScientificWorldJournal       Date:  2013-05-22

Review 10.  Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment.

Authors:  Nancy Martínez-Montiel; Nora Hilda Rosas-Murrieta; Mónica Martínez-Montiel; Mayra Patricia Gaspariano-Cholula; Rebeca D Martínez-Contreras
Journal:  Biomed Res Int       Date:  2016-08-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.